Lexicon Operating Margin from 2010 to 2024

LXRX Stock  USD 0.80  0.02  2.44%   
Lexicon Pharmaceuticals Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin is likely to outpace its year average in 2024.
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 526.3 K, Interest Expense of 13.8 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0 or PTB Ratio of 5.52. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Latest Lexicon Pharmaceuticals' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Lexicon Pharmaceuticals over the last few years. It is Lexicon Pharmaceuticals' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (36.40) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Lexicon Operating Margin Regression Statistics

Arithmetic Mean(101.44)
Coefficient Of Variation(188.38)
Mean Deviation118.61
Median(7.45)
Standard Deviation191.08
Sample Variance36,513
Range725
R-Value(0.46)
Mean Square Error30,905
R-Squared0.21
Significance0.08
Slope(19.77)
Total Sum of Squares511,183

Lexicon Operating Margin History

2024 -135.52
2023 -142.65
2022 -724.89
2021 -292.25
2020 -7.45
2019 0.44
2018 -1.63

About Lexicon Pharmaceuticals Financial Statements

Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.